[{"orgOrder":0,"company":"Alchemab","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Antibody","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Alchemab \/ RA Capital Management","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ RA Capital Management"},{"orgOrder":0,"company":"Alchemab","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ AstraZeneca"},{"orgOrder":0,"company":"Alchemab","sponsor":"Medicines Discovery Catapult","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Human Monoclonal Antibody","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ Alchemab","highestDevelopmentStatusID":"2","companyTruncated":"Alchemab \/ Alchemab"},{"orgOrder":0,"company":"Alchemab","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Alchemab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ Eli Lilly"}]